Comments on:

Drug manufacturer agrees to $500 million penalty

Back to the article » |
WASHINGTON (AP) — A subsidiary of India's largest pharmaceutical company has agreed to pay a record $500 million in fines and penalties for selling adulterated drugs and lying to federal regulators in a case that is part of an ongoing crackdown on the quality of generic drugs flowing into the U.S. Federal prosecutors say the guilty plea by Ranbaxy USA Inc. represents the largest financial...

To learn more about commenting on and our community guidelines, please see our comments FAQ.